DNB Asset Management AS Sells 1,114 Shares of Regeneron Pharmaceuticals, Inc. $REGN

DNB Asset Management AS reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,157 shares of the biopharmaceutical company’s stock after selling 1,114 shares during the quarter. DNB Asset Management AS’s holdings in Regeneron Pharmaceuticals were worth $35,627,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of REGN. Sound Shore Management Inc CT purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $64,677,000. Rakuten Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $33,121,000. Ellerson Group Inc. ADV grew its stake in Regeneron Pharmaceuticals by 49.2% in the 3rd quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock worth $4,556,000 after buying an additional 2,671 shares in the last quarter. Nordea Investment Management AB grew its stake in Regeneron Pharmaceuticals by 118.1% in the 4th quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after buying an additional 74,350 shares in the last quarter. Finally, Oppenheimer & Co. Inc. grew its stake in Regeneron Pharmaceuticals by 7.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 23,714 shares of the biopharmaceutical company’s stock worth $13,334,000 after buying an additional 1,597 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 2.1%

Shares of REGN opened at $698.25 on Friday. The firm has a market cap of $73.82 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 1.55 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The firm has a 50 day moving average price of $744.69 and a 200-day moving average price of $744.97.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the business posted $8.22 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.1 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Analyst Ratings Changes

A number of research firms have commented on REGN. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $825.00 to $800.00 and set an “equal weight” rating for the company in a research note on Thursday, April 30th. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Finally, Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $826.59.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.